New use for BladderChek test imminent:
This article was originally published in Clinica
Matritech has moved closer in the US to expanding the use of its 30-minute, doctor's office bladder cancer test, after the FDA deemed the test approvable for helping to diagnose the disease. The NMP22 BladderChek test was cleared last year for monitoring patients previously diagnosed with bladder cancer. Permission for the expanded indication depends on the successful completion of a routine manufacturing facility inspection, which the Newton, Massachusetts firm expects "to be completed promptly".